PREVENTION OF AUTOIMMUNE DIABETES (GPPAD)
WITHOUT TYPE 1 DIABETES
Joint Effort across Europe.
Welcome to our Sites.
Lead investigator:
Prof Anette-Gabriele Ziegler & Dr Christiane Winkler
Phone: 00800-33 15 33 15
Email: cc@gppad.org
Lead investigator:
Prof Ezio Bonifacio & Dr Gita Gemulla
Phone: 0800-72 45 148
Email: diabetesstudie.crtd@tu-dresden.de
Lead investigator:
Prof Dr Olga Kordonouri
Phone: 0800-37 33 37 15
Email: freder1k@hka.de
Lead investigator:
Prof Kristina Casteels
Phone: +32-(0)-16-348554
Email: freder1kstudie@uzleuven.be
Lead investigator:
Prof Steve Robson & Dr Claire Wood
Phone: +44-(0)-191-2820553
Email: sharon.king10@nhs.net
Lead investigator:
Dr Agnieszka Szypowska & Dr Mariusz Ołtarzewski
Phone: +48-(0)-22 317 94 44
Email: kontakt@swiatbezjedynki.pl
Lead investigator:
Prof Helena Elding Larsson & Prof Dr Markus Lundgren
Phone: +46-(0)-40-39 11 33
Email: gppad@med.lu.se
Lead investigator:
Dr Rachel Besser
Phone: +44-(0)-1865-572258
Email: INGR1D@wrh.ox.ac.uk
Lead investigator:
Dr Katarzyna Gajewska-Knapik & Dr M Loredana Marcovecchio
Phone: +44 (0) 1223 274228
Email: cuh.rosieresearch@nhs.net
Lead investigator:
Heikki Hyöty & Sami Oikarinen
Phone: +358-50-5168480
Email: heikki.hyoty@tuni.fi
Lead investigator:
Encarnita Mariotti-Ferrandiz
Email: encarnita.mariotti@sorbonne-universite.fr
Lead investigator:
Timothy Tree
Email: timothy.tree@kcl.ac.uk
Lead investigator:
Margarita Dominguez-Villar
Email: m.dominguez-villar@imperial.ac.uk
Lead investigator:
Kathleen Gillespie
Email: K.M.Gillespie@bristol.ac.uk
Lead investigator:
Tomi Pastinen
Email: tpastinen@cmh.edu
Lead investigator:
Prof Dr Birgit Rami-Merhar, MBA
Medizinische Universität Wien
Universitätsklinik für Kinder- und Jugendheilkunde
Währinger Gürtel 18-20
1090 Wien
freder1k@meduniwien.ac.at
Lead investigator:
Prof Emanuele Bosi
Phone: +39 02 2643 2625
Email: tarantola.giulia@hsr.it
-
Dr. Agnieszka Szypowska | Warszawa, Poland -
Prof. Dr. Helena Elding Larsson | Malmö, Sweden -
Prof. Dr. Kristina Casteels | Leuven, Belgium -
Dr. Mariusz Ołtarzewski | Warszawa, Poland -
Prof. Dr. Anette-Gabriele Ziegler | Munich, Germany -
Prof. Dr. Steve Robson | Newcastle, UK -
Prof. Dr. Ezio Bonifacio | Saxony, Germany -
Prof. Dr. Markus Lundgren | Malmö, Sweden -
Prof. Dr. Olga Kordonouri | Hanover, Germany
WHAT IS GPPAD?
Preventing Type 1 Diabetes together.
The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) was established in 2015 as a consortium of European research institutions. It aims to facilitate a coordinated, multidisciplinary approach to genetic screening and the conduct of primary prevention studies for type 1 diabetes. The overarching goal of GPPAD studies is to significantly reduce the incidence of islet autoimmunity and type 1 diabetes in children. To achieve this, clinical research sites from Belgium (Leuven), Germany (Dresden, Hanover, Munich), Poland (Warsaw), Sweden (Malmö), the United Kingdom (Oxford, Cambridge, Newcastle), Austria (Vienna), and Italy (Milan) collaborate.
OVER 680,000 EUROPEAN CHILDREN ARE IN.
Our Screenings and Studies.
GPPAD conducts newborn screening in the general population to identify infants at high genetic risk of developing islet autoimmunity and type 1 diabetes. GPPAD investigators provide expert counseling to these families and invites them to participate in primary prevention studies. To date, over 680,000 infants have undergone screening, and more than 2,400 children are participating in the GPPAD prevention studies, POInT, SINT1A, and AVAnT1A. GPPAD also encompasses expert groups for celiac disease and allergy research.
SHARING DATA TO DRIVE INNOVATIONS.
Repository for biospecimen and data.
Furthermore, GPPAD provides researchers worldwide with the opportunity to conduct innovative research on biospecimens from the GPPAD studies, aiming to make significant advances in the study of the etiology, pathogenesis, and prevention of type 1 diabetes and other immune-mediated diseases.
JOINT EUROPEAN EFFORT.
Coordinated from Munich.
The GPPAD coordination center is situated at the Institute of Diabetes Research at Helmholtz Munich, with the Klinikum rechts der Isar of the Technical University of Munich acting as the sponsor for clinical trials in GPPAD.